Histrelin
Also referenced as: Supprelin LA, Vantas
A potent GnRH agonist delivered by implant for sustained hormonal suppression.
- Evidence grade
- BModerate Human Evidence
Moderate Human Evidence
- Regulatory status
- FDA Approved for Specific Indication
Supprelin LA is FDA-approved for central precocious puberty. Vantas was historically approved for palliative advanced prostate-cancer treatment but discontinued.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A potent GnRH agonist delivered by implant for sustained hormonal suppression.
Supprelin LA is FDA-approved for central precocious puberty. Vantas was historically approved for palliative advanced prostate-cancer treatment but discontinued.
Supprelin LA and discontinued Vantas do not have identical availability or indications.
Why It's Being Studied
- Central precocious puberty
- Historical prostate-cancer treatment
Mechanism of Action
Continuous receptor stimulation desensitizes pituitary gonadotropin release after an initial flare.
Continuous receptor stimulation desensitizes pituitary gonadotropin release after an initial flare. Supprelin LA and discontinued Vantas do not have identical availability or indications.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Central precocious puberty
- Historical prostate-cancer treatment
- Approved subcutaneous implant
Evidence Summary
Clinical evidence supports central precocious puberty treatment; a separate historical product had a prostate-cancer indication.
Higher tiers carry more weight. Filled tiers have evidence for Histrelin; tap to read it.
- Clinical evidence supports central precocious puberty treatment; a separate historical product had a prostate-cancer indication.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Clinical evidence supports central precocious puberty treatment; a separate historical product had a prostate-cancer indication.
Reported Adverse Events in Research
- Implant insertion or removal complications, initial flare, psychiatric and seizure warnings are relevant.
Limitations of Current Evidence
- Supprelin LA and discontinued Vantas do not have identical availability or indications.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Histrelin | Trofinetide | |
|---|---|---|
| Evidence grade | B — Moderate Human Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Approved subcutaneous implant | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Histrelin — prescribing label